Low immunoexpression scores for the various MMR proteins were overall more frequent in residual mature TE cases (5/9, 55.6% for MLH1; 8/9, 88.9% for PMS2; 6/9, 66.7% for MSH2; and 4/9, 44.4% for MSH6) when compared to non-TE viable disease (2/6, 33.3% for MLH1 and PMS2; 3/3, 50% for MSH2; and 1/4, 25% for MSH6), but the difference did not reach statistical significance ( Supplementary Figure S9A–D , respectively). 3.
← all excerpts
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.
1
—
—